ALNYLAM PHARMACEUTICALS, INC. (ALNY)
↓ Download CSV- Sector Manufacturing
- Fiscal year ends Dec 31
In fiscal 2025, ALNYLAM PHARMACEUTICALS, INC. reported revenue of $3.71B, up 65.2% from the prior year. The company was profitable, with a net margin of 8.4%. It held $4.97B in total assets against $4.18B in total liabilities.
Key ratios (FY2025)
13.5%
Operating margin
8.4%
Net margin
39.8%
Return on equity
+65.2%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.71B | $2.25B | $1.83B | $1.04B | $844.29M | $492.85M | $219.75M | $74.91M | $89.91M | $47.16M |
| Cost of Revenue | $677.17M | $306.51M | $268.22M | $140.17M | $115.00M | $74.19M | $25.06M | $1.80M | $0 | — |
| Operating Income | $501.58M | -$176.88M | -$282.18M | -$785.07M | -$708.65M | -$828.44M | -$939.43M | -$814.67M | -$500.09M | -$424.59M |
| Net Income | $313.75M | -$278.16M | -$440.24M | -$1.13B | -$852.82M | -$858.28M | -$886.12M | -$761.50M | -$490.87M | -$410.11M |
| EPS (Diluted) | $2.33 | $-2.18 | $-3.52 | $-9.30 | $-7.20 | $-7.46 | $-8.11 | — | — | — |
| Total Assets | $4.97B | $4.24B | $3.83B | $3.55B | $3.64B | $3.41B | $2.40B | $1.57B | $1.99B | $1.26B |
| Total Liabilities | $4.18B | $4.17B | $4.05B | $3.70B | $3.06B | $2.39B | $956.44M | $272.84M | $228.30M | $342.59M |
| Shareholders' Equity | $789.18M | $67.09M | -$220.64M | -$158.22M | $588.20M | $1.02B | $1.44B | $1.30B | $1.77B | $920.22M |
| Cash & Equivalents | $1.66B | $966.43M | $812.69M | $866.39M | $819.98M | $496.58M | $547.18M | $420.15M | $645.36M | $193.62M |
| Operating Cash Flow | $524.08M | -$8.31M | $104.16M | -$541.27M | -$641.69M | -$614.96M | -$278.43M | -$562.62M | -$382.79M | -$307.70M |
| Capital Expenditures | $58.70M | $34.28M | $62.21M | $72.06M | $76.37M | $70.36M | $140.16M | $126.89M | $104.21M | $64.56M |
| Shares Outstanding | 132.38M | 129.29M | 125.79M | 123.92M | 120.18M | 116.43M | 112.19M | 101.18M | 99.67M | 85.94M |